Novolog (Pharm-Up 1966) Ltd (NVLG) Fair Value & Analysis
Healthcare · Il · Market cap 341M ILA
Fair value as of: Jul 12, 2026
From 17 valuation models · updated 29 days ago
Fair value updated Jul 12, 2026, revised from 0.5500 ILA to 0.2300 ILA (−58.2%) since Jun 24, 2026. Share price +17.4% over the past month.
Below-average quality, and screening another 66% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (0.3100 ILA). The favourable scenario is already priced in.
- Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts.
- A fairly wide model range (0.1300 ILA to 0.3100 ILA) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range 0.5692 ILA – 2.77 ILA · fair‑value band 0.1300 ILA – 0.3100 ILA · the 0.6680 ILA price screens above the 0.2300 ILA fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Novolog (Pharm-Up 1966) Ltd (NVLG) currently trades at 0.6680 ILA, while our model-based Fair Value estimate is 0.2300 ILA, implying the stock looks roughly 65.6% overvalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Novolog (Pharm-Up 1966) Ltd generated revenue of 1.8B ILA at a net margin of 0.2%. Revenue declined 0.2% year over year. It earns a return on equity of 0.9%. Net debt stands at 61.4M ILA. Fundamentals as of Jul 12, 2026
Our scenario range runs from 0.1300 ILA (bear case) to 0.3100 ILA (bull case); at 0.6680 ILA, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at -66%, NVLG screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 17 models by family
Widest divergence: DCF Models (2.16 ILA) versus Earnings-Based (0.0800 ILA). Highest evidence: Residual Income (76).
Notify me when NVLG reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 41 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. The company operates through three divisions: Logistics, Healthcare Services, and Digital.
Full company description
Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. The company operates through three divisions: Logistics, Healthcare Services, and Digital. The Logistics division engages in the import and distribution of pharmaceuticals and medical products; logistics of clinical trials and related services; provision of pharmaceutical services to customers; and sterilization and validation processes of consumable medical equipment. The Healthcare Services division provides personalized medicine, medical and diagnostic laboratory, and other medical services to patients, health organizations, insurance companies, multinational companies, and government bodies. The Digital division identifies and develops technological tools for health services; deals with making medical information accessible to the public through medical websites; promotes digital presence for clinics, doctors therapists, and medical bodies; provides services and management tools; and operates and markets digital platforms for doctors and clinics. In addition, the company provides appointment scheduling, calendar management, and telemedicine meeting management. Novolog (Pharm-Up 1966) Ltd was incorporated in 1966 and is headquartered in Modi'in-Maccabim-Re'ut, Israel.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Novolog (Pharm-Up 1966) Ltd reported revenue of 1.8B ILA in FY2025 versus 1.3B ILA in FY2021, a compound +9.5%/yr. Reported net income was 4.1M ILA in FY2025, compounding −44.2%/yr from FY2021.
of which total revenue +11.4 pp · buybacks/dilution −4.3 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
NVLG screens 66% overvalued. Compare with McKesson Corporation →
Peer Group
Medical Distribution · 81 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $805.96 | $819.31 | +2% |
| Cencora, Inc COR | $303.44 | $175.74 | -42% |
| Cardinal Health, Inc CAH | $224.94 | $141.77 | -37% |
| Henry Schein, Inc HSIC | $87.82 | $74.67 | -15% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.70 | ¥33.96 | +103% |
| Sinopharm Group 1099 | HK$16.74 | HK$61.33 | +266% |
| Galenica AG GALE | CHF 87.05 | CHF 61.79 | -29% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.50 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥4.99 | ¥9.84 | +97% |
| Asker Healthcare Group ASKER | kr 79.45 | kr 25.69 | -68% |
Compare Novolog (Pharm-Up 1966) Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Novolog (Pharm-Up 1966) Ltd (NVLG) overvalued or undervalued?
What is the fair value of NVLG?
What is the quality score of NVLG?
What is the revenue of Novolog (Pharm-Up 1966) Ltd (NVLG)?
What is the net profit margin of NVLG?
Does Novolog (Pharm-Up 1966) Ltd pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Novolog (Pharm-Up 1966) Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.